Cenerimod

Viatris published Phase 2b CARE study results for cenerimod in Lancet Rheumatology, showing 4 mg dose improved SLE disease activity vs. placebo. Biomarker data also published in Annals of the Rheumatic Diseases, highlighting cenerimod's immunomodulatory properties.

Cenerimod 4 mg reduced IFN-associated biomarkers in SLE patients, with greater effects in IFN-1 high patients, supporting its use in phase 3 trials.

UCB and Biogen report positive Phase III PHOENYCS GO trial results for dapirolizumab pegol in moderate-to-severe SLE, with a second Phase 3 trial, PHOENYCS FLY, planned for 2024. The SLE market is expected to grow from USD 3.2 billion in 2023, driven by emerging therapies like Litifilimab, Ianalumab, and Cenerimod.

Viatris' Q4 2023 earnings missed estimates with 61 cents per share and $3.8 billion in revenues, down 1% year-over-year. Despite a 14% sales increase in Emerging Markets, overall performance was mixed. The company paid down $500 million in debt and entered a R&D collaboration with Idorsia Ltd. for two phase III assets. 2024 revenue is projected between $15.25-$15.75 billion, with EPS expected at $2.70-$2.85.